Intestinal FDG Uptake

0
Pipeline Programs
1
Companies
1
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
0
0
0
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

1 companies ranked by most advanced pipeline stage

Bausch Health
Bausch HealthQUEBEC, Quebec, Canada
1 program
RifaximinN/A1 trial
Active Trials
NCT01542541CompletedEst. Oct 2012

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
Bausch HealthRifaximin

Clinical Trials (1)

A Clinical Study to Limit Physiologic Intestinal FDG Uptake Uptake on PET-CT Scans

Start: Jul 2011Est. completion: Oct 2012
N/ACompleted

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

1 companies competing in this space